WHITNEY MAYS: Open Payments
NPI 1790946358 · COEBURN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 21 payments from 8 companies in 2025. Trend: 2023 $293 · 2024 $488 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $158 |
| AstraZeneca Pharmaceuticals LP | 8 | $141 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Lundbeck LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 2 | $26 |
| Gilead Sciences, Inc. | 1 | $23 |
| Galderma Laboratories, L.P. | 1 | $23 |
| ABBVIE INC. | 1 | $22 |
Products named: CAPLYTA, FARXIGA, XIFAXAN, VYEPTI, Auvelity, NEMLUVIO, UBRELVY, AIRSUPRA.
Industry payments across VA — which companies pay providers there.
